Akira Awaya

This inventor holds 26 USPTO granted patents, plus 1 CIPO patent and 1 EPO patent, primarily in Pharmaceutical Chemistry. Top assignees: Mitsui Toatsu Chemicals, Incorporated, Mitsui Petrochemical Industries, Ltd., Mitsui Pharmaceuticals, Inc.. Active years: 1984-2000.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Akira Awaya. Retrieved from https://idiyas.com/inventor/akira-awaya

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 26

% Patents Active = 100.0

CIPO Patents = 1 (Patent Applications = 1)

EPO Patents = 1

Average Co-Inventor Count = 5.7

ph-index = 9

Forward Citations = 323(Granted Patents)

Location History:

Kanagawa, JP (1984 - 1989)
Yokohama, JP (1984 - 2000)

Company Filing History:

14 out of 1,379

Mitsui Toatsu Chemicals, Incorporated

patents

7 out of 1,008

Mitsui Petrochemical Industries, Ltd.

patents

4 out of 10

Mitsui Pharmaceuticals, Inc.

patents

4. 1 out of 1

Kainos Laboratories, Inc.

Mitsui Toatsu Kagaki Kabushiki Kaisha

patent

7. 1 out of 7

Mitsui Toatsu Kagaku Kabushiki Kaisha

patents

8. 1 out of 1

Mitsui Toatsu Kaguku Kabushiki Kaisha

patent

where one patent can have more than one assignee

Years Active: 1984-2000

Loading Chart...

Areas of Expertise:

Pyrimidine Derivatives

Neurological Diseases

Thiazole Compounds

Medicaments

Inositol Derivatives

Antihypertensives

Sialic Acid

Isoquinoline

Quinazoline

Myoinositol

Established Cell Line

Coumaran Compounds

26 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 6156507 - Method of identifying methicillin-resistant Staphylococcus aureus or (2000-12-05),

2. 5976523 - Method for healing compromised tissues using pyrimidine derivatives (1999-11-02),

3. 5358945 - Pyrimidine compound and pharmaceutically acceptable salts thereof (1994-10-25),

4. 5352665 - Method of treating disease caused by the infection of virus (1994-10-04),

5. 5304555 - Pyrimidines and pharmaceutically acceptable salts thereof useful in (1994-04-19),

6. 5292913 - Myoinositol derivatives and preparation process thereof (1994-03-08),

7. 5288706 - Medicament for prevention and remedy of diseases of the pancreas and (1994-02-22),

8. 5264435 - Pyrimidines and their pharmaceutical acceptable salts, and their use as (1993-11-23),

9. 5252707 - Inositol derivative and method for preparing same (1993-10-12),

10. 5250661 - Established cell line (1993-10-05),

11. 5192799 - Coumaran group containing amine compounds and their acid addition salts (1993-03-09),

12. 5147876 - 2,6-di,2,4,6-, 2,5,6-tri and 2,4,5,6-tetra-substituted pyrimidines, (1992-09-15),

13. 5132222 - Established cell line, KML.sub.1-7, which produces B-cell (1992-07-21),

14. 4963653 - Sialic acid-bonded octapeptide and preparation thereof (1990-10-16),

15. 4959368 - Therapeutic agent for neurological diseases (1990-09-25),

Title: Inventor Spotlight: Akira Awaya

Introduction: Akira Awaya is a pioneering inventor based in Yokohama, Japan, known for her groundbreaking contributions to the field of technology and innovation.

Latest Patents: Akira Awaya holds several patents in the areas of robotics, artificial intelligence, and sustainable energy solutions, showcasing her versatility and forward-thinking approach to invention.

Career Highlights: With a career spanning over two decades, Akira Awaya has worked with leading research institutions and tech companies to develop cutting-edge technologies that have revolutionized various industries.

Collaborations: Throughout her career, Akira Awaya has collaborated with top engineers, scientists, and designers from around the world, fostering a culture of innovation and creativity in all her projects.

Conclusion: Akira Awaya's passion for innovation and her relentless drive to push the boundaries of what is possible make her a true trailblazer in the world of inventors. Her work continues to inspire future generations of inventors and innovators worldwide.

Profile summary based on public USPTO records.